28. 全身性アミロイドーシス Systemic amyloidosis Clinical trials / Disease details


臨床試験数 : 267 薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-002210-31-DE
(EUCTR)
31/05/201924/01/2019An allocation by random phase II/III trial of doxycycline in comparison to standard therapy in newly-diagnosed cardiac AL amyloidosis patients with bortezomib-based therapyA randomized phase II/III trial of doxycycline vs. standard supportive therapy in newly-diagnosed cardiac AL amyloidosis patients undergoing bortezomib-based therapy - ReDox Light chain (AL) amyloidosis is a protein conformational disease, caused by a small bonemarrow plasma cell clone producing light chains (LCs) that undergo conformational changes,aggregate and deposit in tissues in the form of amyloid fibrils. This process causes dysfunctionof the organs involved and leads to death if not effectively treated.;Therapeutic area: Not possible to specifyTrade Name: DoxyHEXAL® tabs 100 mg Tabletten
Product Name: DoxyHEXAL® tabs 100 mg Tabletten
INN or Proposed INN: DOXYCYCLINE
Amyloid Center - Biotechnology Research Laboratories Policlinico San MatteoNULLNot RecruitingFemale: yes
Male: yes
120Phase 2;Phase 3Canada;Turkey;Germany;Italy
2NCT03474458
(ClinicalTrials.gov)
February 11, 201916/3/2018A Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based TherapyA Randomized Phase II/III Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based TherapyCardiac AL AmyloidosisDrug: Doxycycline;Drug: Standard of care therapyIRCCS Policlinico S. MatteoNULLActive, not recruiting18 YearsN/AAll19Phase 2/Phase 3Canada;France;Germany;Greece;Italy;Spain;Turkey;United Kingdom
3NCT02207556
(ClinicalTrials.gov)
October 1, 201423/7/2014Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis TrialDoxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis (DUAL) Trial: A Phase II Open Label Study of Oral Doxycycline Administered as an Adjunct to Plasma Cell Directed Therapy in Light Chain (AL) AmyloidosisPrimary Systemic AmyloidosisDrug: DoxycyclineMedical College of WisconsinNULLActive, not recruiting18 YearsN/AAll32Phase 2United States